Analysts with RBC Capital have increased their price target of Boston Scientific to $20, according to a report by The Legacy.
RBC Capital rated the company’s stock at “outperform.” Boston Scientific stock has a 52-week high of $18.40 and a 52-week low of $11.10, according to the report.
More articles on gastroenterology:
7 things for gastroenterologists to know for today – April 17, 2015
Alternative payment models in GI: What’s on the horizon?
3 GI physicians making headlines – April 17, 2015
Pinnacle Gastroenterology is expected to open a multi-physician gastroenterology practice in a building that housed the now-shuttered Arkansas Diagnostic Center…
Former Nashville-based Vanderbilt University gastroenterologist Terrence Allen Smith, MD, died at VUMC on April 7 following a bicycle accident, according…
Despite gastroenterologist pay falling by 3% between 2024 and 2025, overall, the specialty has seen a 33.78% pay hike since…
Comments are closed.